JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 7 No. 1 50-59
© 1966 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rhoton, A. L.
Right arrow Articles by Ter-Pogossian, M. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Rhoton, A. L., Jr.
Right arrow Articles by Ter-Pogossian, M. M.

Comparative Study of Mercury-197 Chlormerodrin And Mercury-203 Chlormerodrin For Brain Scanning1,5

Albert L. Rhoton, Jr., M.D.2,6, John Eichling, M.S.3 and Michel M. Ter-Pogossian, Ph.D.4

St. Louis, Missouri

ABSTRACT

This paper reported results of several types of studies done in an effort to determine factors favoring use of either mercury-197 or mercury-203 chlormerodrin for brain scanning. Factors found to favor mercury-203 are the better tissue penetration of its emitted photons, less scattered radiation and the achivement of a better tumor to nontumor ratio of externally detectable count rates.

Factors favoring mercury-197 over mercury-203 are emission of a greater number of useful photons and the lower renal radiation dose. Clinical results with the two agents were comparable. It is felt that mercury-197 chlormerodrin's lower renal radiation dose makes it the more favorable agent for widespread use. The lower renal radiation dose also makes the examination more attractive as a repeatable procedure for following the course of patients with intracranial disease.

FOOTNOTES

1 Aided by a grant from the Allen P. and Josephine B. Green Foundation and United States Public Health Grants #HE-07298, 1-F11-NB-1480-01 and 5-PO-1-NB-04513-02.

5 From the Division of Neurological Surgery, Beaumont-May Institute of Neurology and Mallinckrodt Institute of Radiology, Washington University Medical School, St. Louis, Missouri 63110

2 Special Fellow of National Institute of Neurological Diseases and Blindness in Neurology and Neurosurgery.

3 Research Associate in Radiophysics.

4 Professor of Radiation Physics, The Mallinckrodt Institute of Radiology.

6 Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1966 by the Society of Nuclear Medicine.